hat
Andriol, akòz mekanis larjeman diferan li yo nan aksyon konpare ak C-17 alfa alkilye esteroyid oral anabolizan, prezante absoliman okenn efatofoksik efè. Pou egzanp, yon etid analize potansyèl Andriol a pou toksisite fwa pa eseye dòz segondè sou matyè tès (400mg chak jou) pou 20 jou, ak Andriol pwodwi pa gen okenn chanjman remakab nan lekti anzim le fwa pandan etid la. Sa a gen ladan tou pasyan ki te administre dwòg la nan alontèm lan (yon deseni oswa pi long).
eng
Andriol, due to its vastly different mechanism of action compared to C-17 alpha alkylated oral anabolic steroids, presents absolutely no hepatotoxic effects. For example, one study analyzed Andriol’s potential for liver toxicity by attempting high dosages on test subjects (400mg daily) for 20 days, and Andriol generated no notable changes in liver enzyme readings during the study. This also includes patients who have been administered the drug in the long-term (a decade or longer).